Factors Associated with Improved Glycemic Control by Direct-Acting Antiviral Agent Treatment in Egyptian Type 2 Diabetes Mellitus Patients with Chronic Hepatitis C Genotype 4

Overview

Journal Diabetes Metab J

Specialty Endocrinology

Date 2017 Sep 5

PMID 28868829

Citations 19

Authors

Alaaeldin Abdelsalam Dawood

Mohamed Zakarya Nooh

Ayman Abdelhaleem Elgamal

Affiliations

Soon will be listed here.

Abstract

Background: The association of chronic hepatitis C virus (HCV) infection with type 2 diabetes mellitus (T2DM) was first reported in 1994. Little is known about the effect of direct-acting antiviral agents (DAAs) on glycemic control in T2DM patients. The aim of the present study was to evaluate the factors associated with improved glycemic control (IGC) by DAA treatment in Egyptian T2DM patients with chronic HCV genotype 4 infection.

Methods: This study included 460 T2DM patients with chronic HCV genotype 4 infection. Four hundred patients received DAAs and 60 patients did not receive DAAs. Patients with sustained virological response after 3 months of DAAs (378 patients) were allocated into two groups: first group included 292 patients (77.2%) with IGC and second group included 86 patients (22.8%) with non-improved glycemic control (NIGC).

Results: In IGC group, 78 patients (26.7%) needed to decrease the dose of antidiabetic treatment. There were no significant differences between IGC and NIGC groups as regards age, sex, and body mass index. The percentage of patients with positive family history of T2DM, those with Child B class and duration of T2DM were significantly higher in NIGC group compared to IGC.

Conclusion: Diabetic patients receiving DAAs should be closely monitored for reduction of antidiabetic drugs especially insulin and sulfonylurea to avoid hypoglycemic events. Improvement of glycemic control with DAAs is more in patients without family history of T2DM, short duration of diabetes mellitus, and mild liver disease.

Citing Articles

Prediction of response to sofosbuvir-based therapy using serum interleukin-12 and single nucleotide polymorphism of the interleukin 28B gene as predictive factors in HCV positive genotype-4 patients.

Mohamed Abdelnajid D, Elmowafy A, Rostaing L, ElRakaiby M Medicine (Baltimore). 2023; 102(28):e34125.

PMID: 37443472 PMC: 10344568. DOI: 10.1097/MD.0000000000034125.

Does Hepatitis C Virus Treatment by Directly Acting Antivirals Obligate Shifting Patients with Type 2 Diabetes from Oral Hypoglycemic Drugs to Insulin Therapy?.

Hagag R, Selim A, Darrag O, Zied H, Aboelnasr M Diabetes Metab Syndr Obes. 2022; 15:1261-1268.

PMID: 35502409 PMC: 9056022. DOI: 10.2147/DMSO.S354023.

Therapy of Chronic Viral Hepatitis: The Light at the End of the Tunnel?.

Saracco G, Marzano A, Rizzetto M Biomedicines. 2022; 10(3).

PMID: 35327336 PMC: 8945793. DOI: 10.3390/biomedicines10030534.

Hepatitis C: Problems to extinction and residual hepatic and extrahepatic lesions after sustained virological response.

Cuesta-Sancho S, Marquez-Coello M, Illanes-Alvarez F, Marquez-Ruiz D, Arizcorreta A, Galan-Sanchez F World J Hepatol. 2022; 14(1):62-79.

PMID: 35126840 PMC: 8790402. DOI: 10.4254/wjh.v14.i1.62.

The impact of HCV eradication on hyperglycemia, insulin resistance, cytokine production, and insulin receptor substrate-1 and 2 expression in patients with HCV infection.

Mahmoud B, Moneim A, Mabrouk D Clin Exp Med. 2021; 22(4):583-593.

PMID: 34757525 DOI: 10.1007/s10238-021-00773-1.

References

Basaranoglu M, Basaranoglu G . Pathophysiology of insulin resistance and steatosis in patients with chronic viral hepatitis. World J Gastroenterol. 2011; 17(36):4055-62. PMC: 3203355. DOI: 10.3748/wjg.v17.i36.4055. View

Chehadeh W, Abdella N, Ben-Nakhi A, Al-Arouj M, Al-Nakib W . Risk factors for the development of diabetes mellitus in chronic hepatitis C virus genotype 4 infection. J Gastroenterol Hepatol. 2008; 24(1):42-8. DOI: 10.1111/j.1440-1746.2008.05503.x. View

Premji R, Roopnarinesingh N, Qazi N, Nylen E . New-Onset Diabetes Mellitus With Exposure to Ledipasvir and Sofosbuvir. J Investig Med High Impact Case Rep. 2016; 3(4):2324709615623300. PMC: 4710113. DOI: 10.1177/2324709615623300. View

Elgouhari H, Zein C, Hanouneh I, Feldstein A, Zein N . Diabetes mellitus is associated with impaired response to antiviral therapy in chronic hepatitis C infection. Dig Dis Sci. 2009; 54(12):2699-705. DOI: 10.1007/s10620-008-0683-2. View

Pattullo V, Heathcote J . Hepatitis C and diabetes: one treatment for two diseases?. Liver Int. 2009; 30(3):356-64. DOI: 10.1111/j.1478-3231.2009.02185.x. View

Atkinson M, Eisenbarth G . Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet. 2001; 358(9277):221-9. DOI: 10.1016/S0140-6736(01)05415-0. View

Moucari R, Forestier N, Larrey D, Guyader D, Couzigou P, Benhamou Y . Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C. Gut. 2010; 59(12):1694-8. DOI: 10.1136/gut.2010.219089. View

Thompson A, Patel K, Chuang W, Lawitz E, Rodriguez-Torres M, Rustgi V . Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3. Gut. 2011; 61(1):128-34. PMC: 3766841. DOI: 10.1136/gut.2010.236158. View

Naing C, Mak J, Ahmed S, Maung M . Relationship between hepatitis C virus infection and type 2 diabetes mellitus: meta-analysis. World J Gastroenterol. 2012; 18(14):1642-51. PMC: 3325531. DOI: 10.3748/wjg.v18.i14.1642. View

10.

Pashun R, Shen N, Jesudian A . Markedly Improved Glycemic Control in Poorly Controlled Type 2 Diabetes following Direct Acting Antiviral Treatment of Genotype 1 Hepatitis C. Case Reports Hepatol. 2016; 2016:7807921. PMC: 4886080. DOI: 10.1155/2016/7807921. View

11.

Walsh M, Jonsson J, Richardson M, Lipka G, Purdie D, Clouston A . Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut. 2005; 55(4):529-35. PMC: 1856185. DOI: 10.1136/gut.2005.069674. View

12.

Pavone P, Tieghi T, DEttorre G, Lichtner M, Marocco R, Mezzaroma I . Rapid decline of fasting glucose in HCV diabetic patients treated with direct-acting antiviral agents. Clin Microbiol Infect. 2016; 22(5):462.e1-3. DOI: 10.1016/j.cmi.2015.12.030. View

13.

Parvaiz F, Manzoor S, Tariq H, Javed F, Fatima K, Qadri I . Hepatitis C virus infection: molecular pathways to insulin resistance. Virol J. 2011; 8:474. PMC: 3206488. DOI: 10.1186/1743-422X-8-474. View

14.

Kawaguchi T, Yoshida T, Harada M, Hisamoto T, Nagao Y, Ide T . Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol. 2004; 165(5):1499-508. PMC: 1618659. DOI: 10.1016/S0002-9440(10)63408-6. View

15.

Vanni E, Bugianesi E, Saracco G . Treatment of type 2 diabetes mellitus by viral eradication in chronic hepatitis C: Myth or reality?. Dig Liver Dis. 2015; 48(2):105-11. DOI: 10.1016/j.dld.2015.10.016. View

16.

Bose S, Ray R . Hepatitis C virus infection and insulin resistance. World J Diabetes. 2014; 5(1):52-8. PMC: 3932427. DOI: 10.4239/wjd.v5.i1.52. View

17.

Antonelli A, Ferrari S, Giuggioli D, Di Domenicantonio A, Ruffilli I, Corrado A . Hepatitis C virus infection and type 1 and type 2 diabetes mellitus. World J Diabetes. 2014; 5(5):586-600. PMC: 4138583. DOI: 10.4239/wjd.v5.i5.586. View